Lopinavir-RTV + EFV + 2 NRTIs in Treatment-Experienced
M98-957 Trial
Lopinavir-RTV + Efavirenz + 2 NRTIs in Treatment-Experienced M98-957: Study Design

**Study Design: M97-957**

- **Background**: Analysis of virologic response with respect to baseline viral phenotype and genotype in protease-experienced persons with HIV infection receiving two doses of lopinavir-ritonavir plus efavirenz plus two NRTIs.

- **Inclusion Criteria** (n = 57)
  - HIV RNA >1000 copies/mL on either sequential or simultaneous therapy with ≥2 PIs.
  - NNRTI naïve.

- **Treatment Arms**
  - Lopinavir-ritonavir 400/100 mg BID (or 533/133 mg BID) + Efavirenz QD + 2 NRTIs.

**LPV-RTV (400/100 or 533/133 mg BID) + EFV + 2 NRTIs** (n=57)

Lopinavir-RTV + Efavirenz + 2NRTIs in Treatment-Experienced M98-957: Results

Week 72: Virologic Response*, by Baseline Lopinavir Phenotype

* “dropouts as censored” analysis

Lopinavir-RTV + Efavirenz + 2 NRTIs in Treatment-Experienced M98-957: Results

Week 72: Virologic Response*, by Baseline Lopinavir Mutation Score

HIV RNA <50 copies/mL (%)

<table>
<thead>
<tr>
<th>Baseline Lopinavir Mutation Score</th>
<th>HIV RNA &lt;50 copies/mL (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-5</td>
<td>87</td>
</tr>
<tr>
<td>6-7</td>
<td>62</td>
</tr>
<tr>
<td>≥8</td>
<td>33</td>
</tr>
</tbody>
</table>

* “dropouts as censored” analysis

**Conclusion:** “The correlation of virological response with baseline lopinavir phenotype and mutation score through 72 weeks observed in this study suggests that HIV resistance testing may be beneficial in optimising the use of lopinavir/r in PI-experienced patients.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

*The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.*